723 Metabolically reprogrammed autologous Th1/Tc1 cell therapy (RAPA-201) yields promising safety and efficacy in post-PD-(L)1 solid tumor patients without lymphodepleting host conditioning
Main Authors: | Lawrence G Lum, Martin Gutierrez, Sunil Patel, Michele Donato, Jee Hyun Park, Tania Felizardo, Daniel H Fowler, Morgan Finlay, Ronit Reich-Slotky, Research Nurse Coordinator |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Similar Items
-
1028 Ex vivo chemotherapy resistance of metabolically reprogrammed autologous Th1/Tc1 cells (RAPA-201): Towards the clinical translation of immune-sparing host conditioning
by: Martin Gutierrez, et al.
Published: (2023-11-01) -
Autologous, lentivirus‐modified, T‐rapa cell “micropharmacies” for lysosomal storage disorders
by: Murtaza S Nagree, et al.
Published: (2022-04-01) -
Steganalysis of Quantization Index Modulation Steganography in G.723.1 Codec
by: Zhijun Wu, et al.
Published: (2020-01-01) -
Transcoding between QCELP 13K and G.723.1 CELP speech coders
by: Lisk, Durodami J. (Durodami Joscelyn), 1976-
Published: (2013) -
338 Comparison of lymphodepleting chemotherapy regimens as preconditioning for T-cell therapies
by: Stefan Zajic, et al.
Published: (2023-11-01)